Literature DB >> 8212824

Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice.

B E Johansson1, B Grajower, E D Kilbourne.   

Abstract

In studies of infection of young Balb/c mice with a mouse virulent strain of X-31 (H3N2) influenza A virus we have shown a profound virus dose-related effect of infection on body weight. Most of this effect is prevented by prior administration of either inactivated whole virus vaccine, which prevents infection, or purified influenza virus neuraminidase, which is infection-permissive, but reduces pulmonary virus replication by 1.5 to 3 orders of magnitude. These studies support the concept of infection-permissive immunization and suggest that levels of virus replication previously shown to be antigenic can be sustained without significant systemic effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212824     DOI: 10.1016/0264-410x(93)90130-p

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.

Authors:  Glendie Marcelin; Hilliary M Bland; Nicholas J Negovetich; Matthew R Sandbulte; Ali H Ellebedy; Ashley D Webb; Yolanda S Griffin; Jennifer L DeBeauchamp; Janet E McElhaney; Richard J Webby
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

Review 3.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

5.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

6.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

7.  Immunity to influenza A H9N2 viruses induced by infection and vaccination.

Authors:  X Lu; M Renshaw; T M Tumpey; G D Kelly; J Hu-Primmer; J M Katz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.

Authors:  S Bantia; C D Parker; S L Ananth; L L Horn; K Andries; P Chand; P L Kotian; A Dehghani; Y El-Kattan; T Lin; T L Hutchison; J A Montgomery; D L Kellog; Y S Babu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.